Onconova Therapeutics (NASDAQ: ONTX) Decreased to Hold at Zacks Investment Research

Onconova (NASDAQ: ONTX) was reduced by  Zacks Research  from a “buy” ranking to a “hold” rating in a research note issued to investors on Thursday, Zacks.com reports.

According to Zacks, “Onconova Therapeutics, Inc. runs as a clinical-stage biopharmaceutical business. It focuses on uncovering as well as creating tiny molecule medication prospects to deal with cancer. The Company‘s products under different stages of growth include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

Numerous other equities research analysts also recently talked about the business. Noble Financial reissued a “get” rating and also issued a $11.00 rate purpose on shares of Onconova Therapeutics in a record on Thursday, September 23rd. Guggenheim dropped their cost target on Onconova Therapeutics from $29.00 to $12.00 and also set a “purchase” score on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 as well as a twelve month high of $28.95. Business has a 50 day moving average price of $2.90 and a two-hundred day relocating ordinary price of $4.16. The business has a market cap of $46.76 million, a P/E proportion of -1.82 and a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last released its quarterly incomes results on Thursday, November 11th. The biopharmaceutical business reported ($ 0.22) incomes per share for the quarter, covering analysts’ consensus estimates of ($ 0.33) by $0.11. Onconova Therapeutics had an unfavorable return on equity of 59.78% and also an unfavorable internet margin of 8,294.27%. The company had profits of $0.06 million throughout the quarter, compared to the agreement price quote of $0.06 million. During the same quarter in the previous year, the company posted ($ 0.45) EPS. As a group, research analysts anticipate that Onconova Therapeutics will post -1.18 EPS for the current year.

A variety of hedge funds have just recently bought and sold shares of ONTX. GSA Capital Partners LLP purchased a brand-new setting in Onconova Therapeutics during the 3rd quarter worth $922,000. Hudson Bay Capital Management LP bought a new position in shares of Onconova Therapeutics in the third quarter worth $635,000. Pura Vida Investments LLC bought a brand-new position in shares of Onconova Therapeutics in the 3rd quarter worth $575,000. CVI Holdings LLC purchased a brand-new position in shares of Onconova Therapeutics in the 3rd quarter worth $493,000. Ultimately, Dimensional Fund Advisors LP acquired a brand-new setting in shares of Onconova Therapeutics in the second quarter worth $509,000. Hedge funds and also various other institutional capitalists possess 13.36% of the company’s stock.

Concerning Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical company, which takes part in the recognition and also development of oncology therapeutics. It focuses on finding as well as creating little molecule medicine candidates to treat cancer cells. The business was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 as well as is headquartered in Newtown, PA

. Obtain a totally free duplicate of the Zacks research record on Onconova Therapeutics (ONTX).

For more information regarding research offerings from Zacks Investment Research, browse through Zacks.com.

This immediate information alert was generated by narrative science innovation and monetary data from Market in order to supply readers with the fastest as well as most accurate coverage. This story was examined by Market’s content team before magazine. 



Before you consider Onconova Therapeutics, you’ll intend to hear this.

Market keeps track of Wall Street’s premier and also best doing research analysts as well as the stocks they recommend to their clients every day. Market has recognized the 5 stocks that cover analysts are silently murmuring to their customers to purchase now prior to the broader market catches on … as well as Onconova Therapeutics had not been on the list.

While Onconova Therapeutics presently has a “Buy” rating among analysts, premier analysts believe these five stocks are better buys.